Mn Services Vermogensbeheer B.V. Trims Stock Holdings in Stryker Co. (NYSE:SYK)

Mn Services Vermogensbeheer B.V. lessened its holdings in shares of Stryker Co. (NYSE:SYK - Free Report) by 3.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 160,700 shares of the medical technology company's stock after selling 6,100 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Stryker were worth $48,123,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bremer Bank National Association raised its position in shares of Stryker by 4.0% in the 4th quarter. Bremer Bank National Association now owns 888 shares of the medical technology company's stock worth $266,000 after acquiring an additional 34 shares in the last quarter. Simon Quick Advisors LLC grew its stake in Stryker by 3.0% in the fourth quarter. Simon Quick Advisors LLC now owns 1,158 shares of the medical technology company's stock worth $347,000 after purchasing an additional 34 shares during the period. Consolidated Portfolio Review Corp raised its holdings in Stryker by 3.6% in the fourth quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company's stock worth $294,000 after purchasing an additional 34 shares in the last quarter. MBL Wealth LLC lifted its position in Stryker by 4.6% during the fourth quarter. MBL Wealth LLC now owns 850 shares of the medical technology company's stock valued at $255,000 after buying an additional 37 shares during the period. Finally, PDS Planning Inc boosted its holdings in shares of Stryker by 3.0% during the 3rd quarter. PDS Planning Inc now owns 1,318 shares of the medical technology company's stock valued at $360,000 after buying an additional 38 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company's stock.

Wall Street Analyst Weigh In

SYK has been the subject of several research reports. Canaccord Genuity Group upgraded shares of Stryker from a "hold" rating to a "buy" rating and increased their price target for the stock from $315.00 to $360.00 in a research note on Wednesday, January 31st. Citigroup lifted their target price on shares of Stryker from $362.00 to $406.00 and gave the company a "buy" rating in a report on Wednesday, April 3rd. Roth Mkm upped their price target on Stryker from $345.00 to $348.00 and gave the stock a "buy" rating in a research note on Wednesday, January 31st. Wells Fargo & Company lifted their price objective on Stryker from $336.00 to $364.00 and gave the company an "overweight" rating in a research note on Wednesday, January 31st. Finally, TD Cowen boosted their target price on Stryker from $365.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday. Three equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Stryker presently has a consensus rating of "Moderate Buy" and an average price target of $338.09.

Stryker Stock Performance

Stryker stock traded down $4.24 during midday trading on Friday, reaching $342.05. 1,056,840 shares of the company traded hands, compared to its average volume of 970,082. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $361.41. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. The business has a 50 day moving average of $350.82 and a two-hundred day moving average of $310.64. The firm has a market capitalization of $130.14 billion, a price-to-earnings ratio of 41.46, a price-to-earnings-growth ratio of 2.79 and a beta of 0.89.

Stryker (NYSE:SYK - Get Free Report) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 EPS for the quarter, beating the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the prior year, the firm earned $3.00 EPS. The business's revenue for the quarter was up 11.8% compared to the same quarter last year. As a group, research analysts predict that Stryker Co. will post 11.86 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be paid a $0.80 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $3.20 annualized dividend and a dividend yield of 0.94%. Stryker's dividend payout ratio (DPR) is 38.79%.

Insider Buying and Selling

In other news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the transaction, the director now directly owns 14,242 shares of the company's stock, valued at approximately $4,856,522. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CAO William E. Berry, Jr. sold 7,690 shares of the company's stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares in the company, valued at $4,856,522. The disclosure for this sale can be found here. In the last three months, insiders have sold 212,109 shares of company stock valued at $72,845,768. 5.90% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.